libbyshope's profile picture. Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)

Paul Cacciatore

@libbyshope

Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)

Astros fan in remission from ovarian cancer attends home-opener. Last April, Janie Morris learned she had stage 3 ovarian cancer. Doctors discovered it on Morris' birthday. khou.com/article/sports…


Stable Disease w/Tumor Shrinkage Reported in Subject 2 Following Single IP Dose of NK100 (allogeneic donor-derived natural killer (NK) cell cancer immunotherapy). ir.fatetherapeutics.com/news-releases/…


Only Certain Gynecologic Malignancies Benefit from Immunotherapy. #SGO2018 curetoday.com/articles/only-…


Women with Recurrent Ovarian Cancer Should Be Screened for Various Biomarkers. curetoday.com/articles/women…


PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer. #SGO2018 cancernetwork.com/sgo/parp-7-amp…


Chlamydia Infection is Associated With Increased Risk of Ovarian Cancer. #AACR2018 aacr.org/Newsroom/Pages…


Repurposing Existing FDA-Approved (HDAC) Inhibitors May Provide New Treatment Approach for ARID1A-mutated ovcrs like ovarian clear cell cancer. wistar.org/news/press-rel…


Promise Seen With Frontline Pembrolizumab + Chemo in Ovarian Cancer. #SGO2018 targetedonc.com/news/promise-s…


Safety Analysis Favors Olaparib in Meta-Analysis Comparing PARP Inhibitors in Ovarian Cancer. #SGO2018 targetedonc.com/conference/sgo…


Early Biomarkers Found for Patients Requiring Dose Reduction With Niraparib in Ovarian Cancer. #SGO2018 targetedonc.com/conference/sgo…


Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer. #SGO2018 targetedonc.com/conference/sgo…


Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer. #SGO2018 targetedonc.com/conference/sgo…


United States Trends

Loading...

Something went wrong.


Something went wrong.